Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From Recordati SpA

Janssen’s Sarich: Randomized Controlled Trials, Real-World Evidence Go Best Together

Janssen’s Troy Sarich outlines why it’s hard to emulate randomized controlled trials with real-world evidence studies, emphasizing that the two are “not in competition.” He also highlights the huge strides made by AI-driven technology firms to provide “research-ready” structured data and new game-changing advances in the area of health sensors.

Research & Development Clinical Trials

USPTO Faces Growing Pressure To Enter Battle Over Drug Pricing

Members of Congress, companies and government agencies want the Patent Office to change policies that they say impede generic drug competition. The latest effort is focused on PTO’s discretionary denial of inter partes review petitions, which is the subject of a bipartisan congressional letter and cert petition to the US Supreme Court.

Intellectual Property Legal Issues

Finance Watch: Prepare For September IPOs To Rebound From August Slowdown

Renaissance Capital expects an initial public offering surge in September; Biomedtracker data show financings for COVID-19 programs fell from Q1 to Q2; Revelation will merge with a special purpose acquisition corporation; Ascendis netted $379.3m in a follow-on offering; and Disc Medicine raised $90m in venture capital.

Financing Innovation

US And EU Approvals In First Half 2021 Underscore US-First Orientation Of Novel Drug Development

Close to 90% of the FDA’s 2021 first half novel approvals were cleared in the US before Europe, while the EU’s EMA acted first on only 15% of its first half marketing authorizations for new active substances. Exclusive Pink Sheet analysis explores use of expedited review schemes, special pathways and other comparative trends.

Approvals Review Pathway
See All

Company Information

  • Industry
  • Distributors
  • Pharmaceuticals
  • Pharmaceuticals
    • OTC, Consumer
    • Specialty Pharmaceuticals
  • Other Names / Subsidiaries
    • Bouchara Recordati
    • Dr. F. Frik Ilaç A.S.
    • Opalia Pharma S.A.
    • Orphan Europe
    • Recordati Pharmaceuticals Ltd.
    • Laboratorios Casen Fleet
    • Italchimici S.p.A.
    • Pro Farma AG
    • Recordati S.A. Chemical and Pharmaceutical Company
    • Recordati Rare Diseases Canada Inc.
    • Natural Point S.r.l.
    • Tonipharm S.A.S.
    • FIMEI S.p.A
    • Rossini Investimenti S.p.A
UsernamePublicRestriction

Register